Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05355298
Other study ID # AMP945-PC-201
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 31, 2022
Est. completion date May 1, 2025

Study information

Verified date March 2024
Source Amplia Therapeutics Limited
Contact Trial Information
Phone +61 3 9123 1140
Email info@ampliatx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicentre, open label, two-part study to determine whether the focal adhesion kinase (FAK) inhibitor AMP945, when given prior to dosing with gemcitabine and nab-paclitaxel, improves response to therapy in first-line patients with unresectable or metastatic pancreatic cancer. Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Part B will determine the efficacy of the AMP945 regimen at the RP2D, and will be run as a Simon Two-stage design; Stage 1 will enrol 26 participants. If ≤5 of the 26 participants show an objective response, then recruitment will be paused and a detailed analysis of futility will be performed. If the study is deemed futile, recruitment will cease. If the study is determined to be not futile or >5 of the 26 participants show an objective response, recruitment will continue, and an additional 24 participants will be enrolled in Stage 2.


Recruitment information / eligibility

Status Recruiting
Enrollment 62
Est. completion date May 1, 2025
Est. primary completion date May 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Provide written informed consent prior to any study procedures and agree to adhere to all protocol requirements. 2. Aged at least 18 years at the time of consent. 3. Confirmed histological or cytological diagnosis of advanced pancreatic adenocarcinoma that is: Part A: metastatic or not surgically resectable. Part B: metastatic, with initial diagnosis of metastatic disease =6 weeks prior to Baseline. 4. Has measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan. 5. Eligible for treatment with nab-paclitaxel and gemcitabine as standard of care therapy. 6. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1, sustained on two separate assessments: the first at least 2 weeks prior to the 1st dose of AMP945 and the 2nd within 72 hours prior to the 1st dose of AMP945. Participants not maintaining an ECOG Performance Score of 0-1 at the second assessment will be excluded from participation. 7. Has a life expectancy of >3 months. 8. Adequate organ function, as defined by the laboratory results below (samples must be obtained =14 days prior to study drug administration): a) Haematology: (i) Absolute neutrophil count (ANC) =1.5 × 109/L; (ii) Platelet count =100,000/mm3 (100 × 109/L); (iii) Haemoglobin (Hgb) =9 g/dL. b) Serum chemistry: (i) Aspartate transaminase (AST) (SGOT), ALT (SGPT) =2.5 × upper limit of normal range (ULN), unless liver metastases are clearly present, then =5 × ULN is allowed; (ii) Total bilirubin =ULN; (iii) Creatinine <1.5 x upper limit of normal (ULN) or estimated glomerular filtration rate (eGFR) >60 mL/min/1.73m2 (calculated using the Cockcroft-Gault equation). c) No clinically significant abnormalities in coagulation results. d) No clinically significant abnormalities in urinalysis results. 9. Agree to use contraception according to protocol Exclusion Criteria: 1. Pregnant or breast-feeding, or plans to become pregnant during the study. 2. Has received any investigational medicinal product (IMP) within 30 days or 5 half-lives (whichever is longer) prior to Day -8. 3. Known brain metastases, unless previously treated and well-controlled for at least 3 months (defined as clinically stable, no oedema, no steroids and stable in 2 scans at least 4 weeks apart). 4. Gastrointestinal condition that could interfere with the swallowing or absorption of study medication. 5. Part A: Has received prior systemic treatments for pancreatic cancer, except those given in the adjuvant setting, and with recurrence more than 6 months after completion of curative/adjuvant treatment. 6. Part B: Has received no previous radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease. Prior treatment with 5-FU or gemcitabine administered as a radiation sensitizer in the adjuvant setting is allowed, provided at least 6 months have elapsed since completion of the last dose and no lingering toxicities are present. Participants having received cytotoxic doses of gemcitabine or any other chemotherapy in the adjuvant setting are not eligible for this study. 7. History of malignancy other than in situ cancer or basal or squamous cell skin cancer in the last 5 years. 8. Major surgery, other than diagnostic surgery (i.e., surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day -8. 9. Known human immunodeficiency virus (HIV) and/or history of Hepatitis B or C infections or known to be positive for Hepatitis B surface antigen (HBsAg) or Hepatitis C Antibody. 10. Known history of myocardial infarction, coronary stenting, stroke, or cerebrovascular accident within 6 months prior to the first dose of study drug. 11. Focal palliative radiotherapy (e.g., to a bony metastasis) within the 14 days prior to Run-in, or more extensive radiotherapy within 28 days prior to Run-in. 12. History of chronic leukemias (e.g., chronic lymphocytic leukemia). 13. History of interstitial lung disease, history of slowly progressive dyspnoea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies. 14. History of connective tissue disorders (e.g., lupus, scleroderma, arteritis nodosa). 15. Clinical signs of active infection and/or a temperature of > 38.0°C at the time of Screening or Baseline. Study entry may be deferred at the discretion of the Principal Investigator (PI). 16. Currently using warfarin. 17. Administration of a live virus vaccine in the 4 weeks prior to Day -8 or plans to receive a live virus vaccine during the study. 18. Clinically significant allergies to AMP945, nab-paclitaxel or gemcitabine (or any of their excipients), including hypersensitivity reactions to human albumin, that are not likely to be well controlled with premedication or other supportive measures. 19. Exhibiting any of the conditions or events outlined in the Contraindications or Special Warnings and Precautions sections of the nab-paclitaxel and/or gemcitabine package inserts. 20. Peripheral neuropathy > Grade 1. 21. Corrected QT interval using Fridericia's correction (QTcF) > 460 ms for males and >480 ms for females. 22. Any clinically relevant medical, social, or psychiatric conditions, or any finding during Screening, which in the Investigator's opinion may put the participant at unacceptable risk or interfere with the study objectives. 23. Prior treatment with AMP945.

Study Design


Intervention

Drug:
AMP945 ascending doses
Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Dose escalation decisions will be made using a standard 3+3 dose-escalation phase 1 oncology study design.
AMP945 RP2D
Part B will determine the efficacy of the AMP945 priming regimen at the recommended phase 2 dose (RP2D) determined in Part A.

Locations

Country Name City State
Australia Epworth Healthcare Box Hill Victoria
Australia Monash Health Clayton Victoria
Australia Gallipolli Medical Research Foundation Greenslopes Queensland
Australia Epworth Healthcare Richmond Victoria
Australia Western Health St Albans Victoria
Australia GenesisCare St Leonards New South Wales
Australia Westmead Hospital Westmead New South Wales
Korea, Republic of National Cancer Centre Gyeonggi-do
Korea, Republic of Seoul National University Bundang Hospital Gyeonggi-do
Korea, Republic of Samsung Medical Centre Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Severence Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Amplia Therapeutics Limited

Countries where clinical trial is conducted

Australia,  Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other Overall response Overall response, based on RECIST, by imaging timepoint Imaging every 56 days per participant, with an expected average duration of 6 months
Other Duration of response (DOR) DOR based on RECIST defined as the time from the date of the first confirmed response to the date of progression or death Imaging every 56 days per participant, with an expected average duration of 6 months
Other Overall survival (OS) OS of participants, defined as time from first dose until death from any cause Imaging every 56 days per participant, with an expected average duration of 6 months
Other Progression free survival (PFS) PFS of participants, defined as time from first dose to date of first observed progression, based on RECIST, or death from any cause (whichever comes first) Imaging every 56 days per participant, with an expected average duration of 6 months
Other Time to progression Time to progression, defined as time from first dosing to date of first observed progression, based on RECIST Imaging every 56 days per participant, with an expected average duration of 6 months
Other Clinical benefit rate (CBR) CBR defined as complete response (CR) + partial response (PR) + stable disease Imaging every 56 days per participant, with an expected average duration of 6 months
Other Effects on tumor antigens Changes in levels of tumour antigens (serum CA19-9) at the end of each treatment cycle compared to baseline Every 28 days per participant, with an expected average duration of 6 months
Other Effects on biomarkers Change in levels of other relevant blood biomarkers including p-FAK, PRO-C3, PRO-C6, PRO-C11, C3M, C6M, and C4G Every 28 days per participant, with an expected average duration of 6 months
Primary Number of Participants with Treatment-Emergent Adverse Events (TEAEs) from Baseline to End of Study TEAEs during study treatment and follow up periods From first dose of study drug to end of study, an expected average of 6 months
Primary Part A: Determination of RP2D The RP2D of AMP945 will be determined based on either the maximum tolerated dose or maximum pharmacodynamic effect, which ever is reached first After Cycle 1 (28 days) for each Part A cohort
Primary Part B: efficacy of AMP945 Overall response rate based on RECIST 1.1 Imaging every 56 days per participant, with an expected average duration of 6 months
Secondary Part A: efficacy of AMP945 Overall response rate based on RECIST 1.1 Imaging every 56 days per participant, with an expected average duration of 6 months
Secondary AMP945 levels in plasma Measurement of maximum concentration (cmax) of AMP945 Days -8, -7, 1, 3, 4, 8 and 10
Secondary AMP945 levels in plasma Measurement of time to cmax (tmax) Days -8, -7, 1, 3, 4, 8 and 10
Secondary AMP945 levels in plasma Measurement of clearance (CL) Days -8, -7, 1, 3, 4, 8 and 10
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study